Bausch+Lomb Results Presentation Deck
Total Bausch+Lomb P&L¹ (Non-GAAP)² - YTD
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals Revenue
Total Revenue
Adj. Gross Profit²
Adj. Gross Margin ²
R&D
R&D percent of Revenues
Adj. SG&A²
Adj. SG&A percent of Revenues²
Adj. EBITA²
Depreciation
Stock Based Compensation
Adj. EBITDA 2,3
Adj. EBITDA Margin²
Adj. Net Income ³
Adj EPS 2,4
2Q22-1022
$1,149M
$358M
$323M
$1,830M
$1,103M
60.3%
$152M
8.3%
$700M
38.3%
$251M
$64M
$27M
$352M
19.2%
$188M
$0.54
2Q21-1Q21
$1,112M
$347M
$356M
$1,815M
$1,115M
61.4%
$138M
7.6%
$668M
36.8%
$309M
$64M
$29M
$398M
21.9%
$209M
$0.60
1. Products with sales outside the United States impacted by F/X changes.
BAUSCH + LOMB 2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
3. Includes transactional FX and NCI.
4. On a proforma basis after giving effect to the IPO.
Reported Change
3%
3%
(9%)
1%
(1%)
(110 bps)
(10%)
(5%)
(19%)
0%
(7%)
(12%)
(10%)
Constant Currency³
8%
8%
(6%)
5%
2%
(13%)
(9%)
(16%)
5%
(7%)
(14%)
(13%)
Organic Change³
8%
10%
(6%)
5%
29View entire presentation